UPDATE 1-Bristol's Opdivo proves effective against second type of lung cancer

April 17 (Reuters) - A large study of Bristol-Myers Squibb Co's Opdivo treatment has been halted after proving the drug is effective against the most common form of lung cancer, the company said, positioning the medicine for far wider use than its already approved lung cancer and melanoma indications.